Publications

Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Intravenous Ketamine for Chronic Nonmalignant Pain

Focus of the Report: This report focuses on the use of intravenous (IV) ketamine for the treatment of chronic nonmalignant pain.

Technology Description: The hydrochloride (HCl) acid salt of ketamine is a rapid-acting phencyclidine anesthetic indicated for the induction of anesthesia prior to the administration of other general anesthetic agents, as a s…

read more

Retifanlimab for Squamous Cell Anal Cancer

Retifanlimab is an investigational intravenous humanized monoclonal antibody that inhibits the activity of programmed death-1 (PD-1). By blocking PD-1, retifanlimab acts as an immune checkpoint inhibitor, freeing T cells to kill cancer cells and boosting immune system response against certain cancers. Retifanlimab is proposed as a monotherapy for locally advanced and metastat…

read more

Liquid Sublingual Immunotherapy

Focus of the Report: This report evaluates the use of liquid sublingual immunotherapy (SLIT) for the treatment of allergic rhinitis in the United States.

Technology Description: Liquid SLIT involves the daily administration of a diluted dose of an allergen under the tongue, which allow…

read more